Immunome, Inc. entered into an agreement to acquire MorphImmune, Inc.
June 29, 2023
Share
Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. on June 29, 2023. Under the terms of the transaction, each share of MorphImmune common stock and each share of MorphImmune preferred stock will be converted into the right to receive a number of shares of Immunome common stock equal to an exchange ratio of 0.3402, and outstanding options to acquire Morphimmune common stock will be assumed by Immunome. A concurrent $125 million private placement investment has also been announced. At the effective time of the merger, prior to giving effect to the private placement, securityholders of Immunome will own approximately 55% of the combined company and securityholders of Morphimmune will own approximately 45% of the combined company on a fully diluted basis. The combined company, which will operate as Immunome and retain the same ticker symbol, will be headquartered in Seattle, WA and will maintain research lab facilities in Exton, PA and West Lafayette, IN. Clay B. Siegall, Chief Executive Officer and President of Morphimmune, will serve as the Chief Executive Officer, President, and Chairman of the Board of Directors of Immunome. In connection with the private placement, Chief Executive Officer of Enavate Sciences, will be appointed to the Board of Directors of Immunome. The board of directors of the combined company will be comprised of seven members: two selected by Morphimmune, who will initially be Clay B. Siegall, and Isaac Barchas; one selected by Immunome, who will initially be Philip Wagenheim; and four additional independent directors, to be mutually agreed, one of whom will initially be James P. Boylan.
The closing of the transaction is subject to customary closing conditions, including the effectiveness of the registration statement on Form S-4 to be filed by Immunome, the receipt of required stockholder approvals from Immunome and Morphimmune stockholders. The Boards of Directors of both companies have approved the transaction. Stockholders of Immunome holding approximately 20% of the voting stock of Immunome and stockholders of Morphimmune holding approximately 70% of the voting stock of Morphimmune executed voting and support agreements to vote in favor of the transaction. Both the merger and private placement are expected to close by the end of Q4 2023.
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.